Skip to main content

Comparison of therapeutic responses to an anticancer drug in three stocks of ICR mice derived from three different sources

Abstract

Korl:ICR mice, established by the Korean National Institute of Food and Drug Safety Evaluation (NIFDS), are characterized based on their genetic variation, response to gastric injury, and response to constipation inducers. To compare the inhibitory responses of ICR stocks obtained from three different sources to the anticancer drug cisplatin (Cis), alterations in tumor volume, histopathological structure, and toxicity were examined in Sarcoma 180 tumor-bearing Korl:ICR, A:ICR (USA source), and B:ICR (Japan source) mice treated with low and high concentrations of Cis (L-Cis and H-Cis, respectively). Tumor size and volume were lower in H-Cis-treated mice than in L-Cis-treated mice in all three ICR stocks with no significant differences among stocks. There was a significant enhancement of the necrotizing areas in the histological structures in the L-Cis- and H-Cis-treated groups relative to that in the untreated group. The necrotizing area changes were similar in the Sarcoma 180 tumor-bearing Korl:ICR, A:ICR, and B:ICR mice. However, there were stock-bases differences in the serum biomarkers for liver and kidney toxic effects. In particular, the levels of AST, ALT and BUN increased differently in the three H-Cis-treated ICR stocks, whereas the levels of ALP and CRE were constant. Taken together, the results of the present study indicate that Korl:ICR, A:ICR, and B:ICR mice have similar overall inhibitory responses following Cis treatment of Sarcoma 180-derived solid tumors, although there were some differences in the magnitude of the toxic effects in the three ICR stocks.

References

  1. 1.

    Rice MC, O’Brien SJ. Genetic variance of laboratory outbred Swiss mice. Nature 1980; 283(5743): 157–161.

    CAS  Article  Google Scholar 

  2. 2.

    Cui S. Chesson C. Hope R. Genetic variation within and between strains of outbred Swiss mice. Lab Anim 1993; 27(2): 116–123.

    CAS  Article  Google Scholar 

  3. 3.

    Chia R. Achilli F. Festing MF, Fisher EM. The origins and uses of mouse outbred stocks. Nat Genet 2005; 37(11): 1181–1186.

    CAS  Article  Google Scholar 

  4. 4.

    O’Connor JC, Lawson MA, André C, Moreau M. Lestage J. Castanon N. Kelley KW, Dantzer R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 2009; 14(5): 511–522.

    Article  Google Scholar 

  5. 5.

    Zhong SZ, Ge QH, Qu R. Li Q. Ma SP. Paeonol attenuates neurotoxicity and ameliorates cognitive impairment induced by dgalactose in ICR mice. J Neurol Sci 2009; 277(1–2): 58–64.

    CAS  Article  Google Scholar 

  6. 6.

    Lynch CJ. The so-called Swiss mouse. Lab Anim Care 1969; 19(2): 214–220.

    CAS  PubMed  Google Scholar 

  7. 7.

    Snell GD. Biology of the Laboratory Mouse. 1st ed. McGraw-Hill, New York, 1941; pp 1–497.

    Google Scholar 

  8. 8.

    Hwang SJ, Cho YM, Shin HJ, Kim HD, Choi KM, Kwon KC, Lee SH, Shin HJ, Shin HD, Chung MW. Stratification of outbred ICR mice stocks by genetic variation. Acad J Biotechnol 2016; 4(11): 365–371.

    Google Scholar 

  9. 9.

    Song SH, Kim JE, Go J. Koh EK, Sung JE, Lee HA, Choi KM, Kim HD, Jung YS, Kim KS, Hwang DY. Comparison of the response using ICR mice derived from three different sources to ethanol/hydrochloric acid-induced gastric injury. Lab Anim Res 2016; 32(1): 56–64.

    Article  Google Scholar 

  10. 10.

    Kim JE, Yun WB, Sung JE, Lee HA, Choi JY, Choi YS, Jung YS, Kim KS, Hwang DY. Characterization the response of Korl:ICR mice to loperamide induced constipation. Lab Anim Res 2016; 32(4): 231–240.

    Article  Google Scholar 

  11. 11.

    Wu HT, Lu FH, Su YC, Ou HY, Hung HC, Wu JS, Yang YC, Chang CJ. In vivo and in vitro anti-tumor effects of fungal extracts. Molecules 2014; 19(2): 2546–2556.

    Article  Google Scholar 

  12. 12.

    da Silva Faria MC, Santos NA, Carvalho Rodrigues MA, Rodrigues JL, Barbosa Junior F. Santos AC. Effect of diabetes on biodistribution, nephrotoxicity and antitumor activity of cisplatin in mice. Chem Biol Interact 2015; 229: 119–131.

    Article  Google Scholar 

  13. 13.

    Frank R. Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2(7): 566–580.

    CAS  Article  Google Scholar 

  14. 14.

    Bueters T. Ploeger BA, Visser SA. The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives. Drug Discov Today 2013; 18(17–18): 853–862.

    Article  Google Scholar 

  15. 15.

    Fan J. de Lannoy IA. Pharmacokinetics. Biochem Pharmacol 2014; 87(1): 93–120.

    CAS  Article  Google Scholar 

  16. 16.

    Kimura T. Natural products and biological activity of the pharmacologically active cauliflower mushroom Sparassis crispa. Biomed Res Int 2013; 2013: 982317.

    Google Scholar 

  17. 17.

    Hashi M. Takeshita T. The host-mediated anti-tumor effect of 4-O-methylgluccuronoxylan. Agric Biol Chem 1979; 43(5): 961–967.

    CAS  Google Scholar 

  18. 18.

    Stefanova TH, Nikolova NJ, Toshkova RA, Neychev HO. Antitumor and immunomodulatory effect of coumarin and 7-hydroxycoumarin against Sarcoma 180 in mice. J Exp Ther Oncol 2007; 6(2): 107–115.

    CAS  PubMed  Google Scholar 

  19. 19.

    Snell GD, Russell E. Fekete E. Smith P. Resistance of various inbred strains of mice to tumor homoiotransplants, and its relation to the H-2 allele which each carries. J Natl Cancer Inst 1953; 14(3): 485–491.

    CAS  PubMed  Google Scholar 

  20. 20.

    Strong LC. Indications of tissue specificity in a transplantable sarcoma. J Exptl Med 1924; 39(3): 447–456.

    CAS  Article  Google Scholar 

  21. 21.

    Bradner WT, Pindell MH. Strain specificity of stimulated regression of sarcoma 180. Cancer Res 1965; 25(6): 859–864.

    CAS  PubMed  Google Scholar 

  22. 22.

    Diller IC, Donnelly AJ, Fisher ME. Isolation of pleomorphic, acid-fast organisms from serveral strains of mice. Cancer Res 1967; 27(8): 1402–1408.

    CAS  PubMed  Google Scholar 

  23. 23.

    Vikis HG, Jackson EN, Krupnick AS, Franklin A, Gelman AE, Chen Q. Piwnica-Worms D. You M. Strain-specific susceptibility for pulmonary metastasis of sarcoma 180 cells in inbred mice. Cancer Res 2010; 70(12): 4859–4867.

    CAS  Article  Google Scholar 

Download references

Acknowledgments

We thank Jin Hyang Hwang, the animal technician, for directing the animals care at the Laboratory Animal Resources Center. This project was supported by a grant of BIOREIN (Laboratory Animal Bio Resources Initiative) from the Ministry of Food and Drug Safety in 2015.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dae Youn Hwang.

Rights and permissions

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sung, J.E., Kim, J.E., Lee, H.A. et al. Comparison of therapeutic responses to an anticancer drug in three stocks of ICR mice derived from three different sources. Lab Anim Res 33, 187–194 (2017). https://doi.org/10.5625/lar.2017.33.2.187

Download citation

Keywords

  • Korl:ICR mice
  • tumor
  • Sarcoma 180 cell
  • cisplatin
  • toxicity